We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......


Arch Intern Med (Chic). 1942;69(4):636-646. doi:10.1001/archinte.1942.00200160087007.
Text Size: A A A
Published online

Until the discovery of sulfanilamide and its derivatives chemotherapy had little of proved value to offer in the treatment of staphylococcic infections. It is true that recoveries from staphylococcic septicemia in human beings have been ascribed to the intravenous administration of gentian violet, neutral acriflavine and various mercurial and other compounds, but none of these substances has materially reduced its high mortality and none has proved of value in the treatment of experimental infections of mice and rabbits under well controlled conditions.

Domagk1 found the original prontosil (the hydrochloride of 4-sulfamido-2′-4′-diaminoazobenzene) somewhat effective in the treatment of experimental staphylococcic infections of mice and later reported2 that better results were observed with uliron (a brand of dimethyldisulfanilamide; paraaminobenzenesulfonylparaaminobenzenedimethylsulfonamide). As shown in table 1, various investigators have found sulfanilamide, sulfapyridine (2- [paraaminobenzenesulfonamido]-pyridine) and, more recently, thiazole derivatives of sulfanilamide effective in varying degrees in the treatment of these experimental infections.


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal

First Page Preview

View Large
First page PDF preview





Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Submit a Comment


Some tools below are only available to our subscribers or users with an online account.

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.